DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Menomune (Meningococcal Polysaccharide Vaccine) - Warnings and Precautions

 
 



WARNING

This product contains dry natural latex rubber as follows: The stopper to the vial contains dry natural latex rubber.

If the vaccine is used in persons receiving immunosuppressive therapy, the expected immune response may not be obtained.

Menomune® -A/C/Y/W-135 should NOT be given at the same time as whole-cell pertussis or whole-cell typhoid vaccines due to combined endotoxin content.20,21

PRECAUTIONS

GENERAL

Care is to be taken by the health-care provider for the safe and effective use of Menomune® -A/C/Y/W-135.

EPINEPHRINE INJECTION (1:1000) MUST BE IMMEDIATELY AVAILABLE TO COMBAT UNEXPECTED ANAPHYLACTIC OR OTHER ALLERGIC REACTIONS.

Prior to an injection of any vaccine, all known precautions should be taken to prevent adverse reactions. This includes a review of the patient's history with respect to possible sensitivity to the vaccine or similar vaccines and to possible sensitivity to dry natural latex rubber.

Special care should be taken to avoid injecting the vaccine intradermally, intramuscularly, or intravenously since clinical studies have not been done to establish safety and efficacy of the vaccine using these routes of administration.

Health-care providers should obtain the previous immunization history of the vaccinee, and inquire about the current health status of the vaccinee.

A separate, sterile syringe and needle or a sterile disposable unit should be used for each patient to prevent transmission of hepatitis and other infectious agents from person to person. Needles should not be recapped and should be disposed of according to biohazard waste guidelines.

INFORMATION FOR PATIENT

Patients, parents or guardians should be fully informed of the benefits and risks of immunization with Menomune® -A/C/Y/W-135.

Patients, parents or guardians should be instructed to report any serious adverse reactions to their health-care provider.

As part of the patient's immunization record, the date, lot number and manufacturer of the vaccine administered should be recorded. 22,23,24

DRUG INTERACTIONS

If Menomune® -A/C/Y/W-135 is administered to immunosuppressed persons or persons receiving immunosuppressive therapy, an adequate immunologic response may not be obtained.

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY

Menomune® -A/C/Y/W-135 has not been evaluated in animals for its carcinogenic, mutagenic potentials or impairment of fertility.

PREGNANCY

REPRODUCTIVE STUDIES-PREGNANCY CATEGORY C

Animal reproduction studies have not been conducted with Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135. It is also not known whether Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 should be given to a pregnant woman only if clearly needed.

Although there is limited data, studies to date have found no evidence of teratogenicity of the polysaccharide quadrivalent meningococcal vaccine when given to pregnant women. 25

NURSING MOTHERS

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Menomune® -A/C/Y/W-135 is administered to a nursing woman.

PEDIATRIC USE

SAFETY AND EFFECTIVENESS OF MENOMUNE® -A/C/Y/W-135 IN CHILDREN BELOW THE AGE OF 2 YEARS HAVE NOT BEEN ESTABLISHED.

Page last updated: 2006-09-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017